Drug
Pulmozyme
Pulmozyme is a pharmaceutical drug with 6 clinical trials. Historical success rate of 100.0%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph early_phase_1
1
17%
Ph phase_3
2
33%
Ph phase_2
2
33%
Ph phase_4
1
17%
Phase Distribution
1
Early Stage
2
Mid Stage
3
Late Stage
Phase Distribution6 total trials
Early Phase 1First-in-human
1(16.7%)
Phase 2Efficacy & side effects
2(33.3%)
Phase 3Large-scale testing
2(33.3%)
Phase 4Post-market surveillance
1(16.7%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
6
all time
Status Distribution
Completed(3)
Other(3)
Detailed Status
unknown3
Completed3
Development Timeline
Analytics
Development Status
Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Early Phase 11 (16.7%)
Phase 22 (33.3%)
Phase 32 (33.3%)
Phase 41 (16.7%)
Trials by Status
unknown350%
completed350%
Recent Activity
0 active trials
Showing 5 of 6
completedphase_4
RhDNase and Biodistribution of PMN Serine Proteases in Cystic Fibrosis Sputum
NCT00843817
unknownphase_2
Pulmozyme to Improve COVID-19 ARDS Outcomes
NCT04402944
completedphase_3
Efficacy and Safety of Tigerase® vs. Pulmozyme® in Patients With Cystic Fibrosis
NCT04468100
unknownphase_2
Dornase Alpha for the Treatment of COVID-19
NCT04432987
completedphase_3
Nasal Inhalation of Dornase Alfa (Pulmozyme) in Patients With Cystic Fibrosis and Chronic Rhinosinusitis
NCT00265434
Clinical Trials (6)
Showing 6 of 6 trials
NCT00843817Phase 4
RhDNase and Biodistribution of PMN Serine Proteases in Cystic Fibrosis Sputum
NCT04402944Phase 2
Pulmozyme to Improve COVID-19 ARDS Outcomes
NCT04468100Phase 3
Efficacy and Safety of Tigerase® vs. Pulmozyme® in Patients With Cystic Fibrosis
NCT04432987Phase 2
Dornase Alpha for the Treatment of COVID-19
NCT00265434Phase 3
Nasal Inhalation of Dornase Alfa (Pulmozyme) in Patients With Cystic Fibrosis and Chronic Rhinosinusitis
NCT00536952Early Phase 1
Pilot Study of Pulmozyme (rhDNase) in Patients With Head and Neck Cancers Treated With Radiation Therapy + Chemotherapy
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6